Company Analysis ASKA Pharmaceutical Holdings Co.,Ltd.
1. Summary
Advantages
- Price (2317 Β₯) is less than fair price (3514.46 Β₯)
- The stock's return over the last year (10.5%) is higher than the sector average (-0.128%).
- The company's current efficiency (ROE=12.96%) is higher than the sector average (ROE=-9.31%)
Disadvantages
- Dividends (2.57%) are below the sector average (2.68%).
- Current debt level 10.45% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| ASKA Pharmaceutical Holdings Co.,Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 5.7% | 0% | 0.1% |
| 90 days | 11.2% | -0% | -6.2% |
| 1 year | 10.5% | -0.1% | -6.4% |
4886 vs Sector: ASKA Pharmaceutical Holdings Co.,Ltd. has outperformed the "Healthcare" sector by 10.63% over the past year.
4886 vs Market: ASKA Pharmaceutical Holdings Co.,Ltd. has outperformed the market by 16.93% over the past year.
Stable price: 4886 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 4886 with weekly volatility of 0.202% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (2317 Β₯) is lower than the fair price (3514.46 Β₯).
Price significantly below the fair price: The current price (2317 Β₯) is 51.7% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (8.37) is lower than that of the sector as a whole (110.96).
P/E vs Market: The company's P/E (8.37) is lower than that of the market as a whole (129.66).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.02) is lower than that of the sector as a whole (70.27).
P/BV vs Market: The company's P/BV (1.02) is lower than that of the market as a whole (96.38).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1) is lower than that of the sector as a whole (74.98).
P/S vs Market: The company's P/S indicator (1) is lower than that of the market as a whole (96.39).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (4.69) is lower than that of the sector as a whole (17.04).
EV/Ebitda vs Market: The company's EV/Ebitda (4.69) is lower than that of the market as a whole (103.77).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 212.51% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (212.51%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1.22%).
5.4. ROE
ROE vs Sector: The company's ROE (12.96%) is higher than that of the sector as a whole (-9.31%).
ROE vs Market: The company's ROE (12.96%) is higher than that of the market as a whole (8.28%).
5.5. ROA
ROA vs Sector: The company's ROA (8.48%) is higher than that of the sector as a whole (-9.76%).
ROA vs Market: The company's ROA (8.48%) is higher than that of the market as a whole (3.9%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.49%) is lower than that of the sector as a whole (9.09%).
ROIC vs Market: The company's ROIC (7.49%) is lower than that of the market as a whole (8.77%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 2.57% is below the average for the sector '2.68%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 2.57% has been steadily paid over the past 7 years, DSI=1.
Weak dividend growth: The company's dividend yield 2.57% has been growing weakly or stagnant over the past 5 years. Growth over only 3 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (10.5%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
